Alpha-1-Antitrypsin-Deficiency in COVID-19 (CORSAAR-AAT)

Universität des Saarlandes

Status: Completed

Conditions: Covid19

Treatments: Drug: AAT( Alpha 1 Antitrypsin)

Study type: Observational

Funder types: Other

Identifiers

NCT04799873

CORSAAR-AAT-001

Details and patient eligibility

About

The blood concentrations of alpha-1-antitrypsin are monitored during COVID-19. The clinical course of patients that received AAT infusion for clinical indication is monitored.

Full description

The blood concentrations of alpha-1-antitrypsin are monitored during COVID-19. The clinical course of patients that received AAT infusion for clinical indication is monitored. Clinical outcomes, blood inflammatory markers, and virus load are monitored.

Enrollment: 10 patients

Sex: All

Ages: 18 to 110 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Infection with SARS-COV2
• Age over 18 years

Exclusion criteria

• Unability to consent
• Invasive ventilation